Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Abstract

The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness–implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.

Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada

“…The Canadian PERSPECTIVE I&I study (Personalized risk assessment for prevention and early detection of breast cancer: Integration and Implementation) is one of the major ongoing initiatives examining the potential of risk-stratified BC screening [ 3 , 19 , 20 ]. As part of this effort, the current study sought to examine attitudes towards, comfort level about, and willingness to take part in BC risk-stratified screening in Canadian women.…”

The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia

“…Screening programs should be socially and ethically acceptable to screening participants [9,10]. Therefore we categorized each protocol as either currently acceptable or not (Table 1).…”

“…These factors include HPV-prevalence, CC incidence and mortality, as well as screening test characteristics, costs for screening, diagnosis and treatment. Also, a new protocol must be clinically, socially and ethically acceptable to the target population, health professionals and society [9,10]. If not, users and suppliers are less likely to adhere to the protocol and the unwanted screening behaviour in terms of less screening, overuse of screening or use of notrecommended screening modalities can alter the predicted benefits to hams ratio including cost-effectiveness of organized screening [11].…”

Synthesis, Characterisation and Cytotoxicity of Gold Nanowires for Ultra-Sensitive Biosensor Development

“…With current emerging proteomics technologies, it is straightforward to obtain reliable sets of disease-speci c protein biomarkers. Early identi cation of disease blood protein signatures, is becoming the most promising strategy for effective cancer prevention [7][8][9][10]. Nevertheless, some protein biomarkers, such as those secreted by cell death in tumours microenvironment at a very early growth period, are produced only at ultra-low concentrations [11][12][13][14].…”